BTK
Gli inibitori della tirosina chinasi di Bruton (BTK) sono composti che mirano specificamente a inibire la BTK, un enzima cruciale coinvolto nella segnalazione del recettore delle cellule B e nella regolazione dell'angiogenesi. La BTK svolge un ruolo significativo nella proliferazione e nella sopravvivenza delle cellule cancerose, in particolare nelle malignità ematologiche. Inibendo la BTK, questi composti possono interrompere l'angiogenesi e la crescita tumorale, rendendoli preziosi nella terapia del cancro. Presso CymitQuimica, offriamo una gamma di inibitori della BTK di alta qualità per supportare la tua ricerca in oncologia, immunologia e angiogenesi.
Trovati 159 prodotti di "BTK"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CGI560
CAS:CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.Formula:C29H27N5OColore e forma:SolidPeso molecolare:461.56Spebrutinib besylate
CAS:Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).Formula:C28H28FN5O6SPurezza:98%Colore e forma:SolidPeso molecolare:581.62Ibrutinib-MPEA
CAS:Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.Formula:C32H39N9O2Colore e forma:SolidPeso molecolare:581.71CHMFL-BTK-01
CAS:<p>CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.</p>Formula:C38H41N5O5Purezza:98%Colore e forma:SolidPeso molecolare:647.76ACP-5862
CAS:ACP-5862, active metabolite of Acalabrutinib, is a BTK inhibitor with an IC50 of 5.0 nM.Formula:C26H23N7O3Colore e forma:SolidPeso molecolare:481.51DPPY
CAS:DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Formula:C25H26ClN7O3Colore e forma:SolidPeso molecolare:507.97EGFR-IN-40
CAS:EGFR-IN-40 (compound 3z) is a potent inhibitor of BTK (IC50: 1.2 nM), EGFR (IC50: 5.3 nM) and ITK (IC50: 46.1 nM).Formula:C23H20N6O3Colore e forma:SolidPeso molecolare:428.44BLK degrader 1
CAS:<p>BLK degrader 1 is a BLK degrader with anticancer activity for cancer research.</p>Formula:C32H25F3N6O2Purezza:99.22% - 99.24%Colore e forma:SolidPeso molecolare:582.58(±)-Zanubrutinib
CAS:(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,Formula:C27H29N5O3Purezza:99.09%Colore e forma:SolidPeso molecolare:471.55CHMFL-EGFR-202
CAS:CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).Formula:C25H24ClN7O2Purezza:99.66%Colore e forma:SolidPeso molecolare:489.96Tilfrinib
CAS:Tilfrinib is an effective and selective inhibitor of breast tumor kinase(Brk, IC50 = 3.15 nM) which displays anti-proliferative and anti-tumor activities.Formula:C17H13N3OPurezza:99.54%Colore e forma:SolidPeso molecolare:275.3(R)-Zanubrutinib
CAS:(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).Formula:C27H29N5O3Purezza:99.55%Colore e forma:SolidPeso molecolare:471.55Larotinib
CAS:Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.Formula:C24H26ClFN4O4Purezza:99.73%Colore e forma:SolidPeso molecolare:488.94NX-2127
CAS:NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferativeFormula:C39H45N9O5Purezza:99.07%Colore e forma:SolidPeso molecolare:719.83Sunvozertinib
CAS:Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.Formula:C29H35ClFN7O3Purezza:98.11% - 99.63%Colore e forma:SolidPeso molecolare:584.08Edralbrutinib
CAS:Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood andFormula:C26H21F2N5O3Purezza:99.41%Colore e forma:SolidPeso molecolare:489.47PF-06250112
CAS:PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.Formula:C22H20F2N6O2Purezza:98%Colore e forma:SolidPeso molecolare:438.43PF-303
CAS:PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.Formula:C22H21ClN6O2Colore e forma:SolidPeso molecolare:436.89DDa-1
CAS:DDa-1 is a potent (kinase degrader) [1].Formula:C60H77Cl2N13O3SColore e forma:SoildPeso molecolare:1131.31Cinsebrutinib
CAS:Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.Formula:C22H26FN3O2Purezza:98%Colore e forma:SolidPeso molecolare:383.46BMX-IN-1
CAS:BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosineFormula:C29H24N4O4SPurezza:98.38%Colore e forma:SolidPeso molecolare:524.59BTK-IN-11
CAS:BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)Formula:C26H22ClN5O3Colore e forma:SolidPeso molecolare:487.94BTK-IN-17
BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.Formula:C26H23N7O2Colore e forma:SolidPeso molecolare:465.51BTK inhibitor 13
CAS:BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).Formula:C29H26FN5O3Purezza:98%Colore e forma:SolidPeso molecolare:511.55Pirtobrutinib
CAS:Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.Formula:C22H21F4N5O3Purezza:99.76% - 99.94%Colore e forma:SolidPeso molecolare:479.43BTK-IN-18
CAS:BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.Formula:C20H22Cl2N6OColore e forma:SolidPeso molecolare:433.33(Rac)-PF-06250112
CAS:(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.Formula:C22H20F2N6O2Purezza:98%Colore e forma:SolidPeso molecolare:438.43BTK-IN-19
CAS:BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .Formula:C21H22Cl2N6OColore e forma:SolidPeso molecolare:445.35BTK inhibitor 20
CAS:BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .Formula:C37H42N8O4Colore e forma:SolidPeso molecolare:662.78TAK-020
CAS:TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.Formula:C18H17N5O3Purezza:98.66%Colore e forma:SolidPeso molecolare:351.36BTK inhibitor 1
CAS:<p>BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.</p>Formula:C24H23FN8O2Purezza:98.24% - 98.91%Colore e forma:SolidPeso molecolare:474.49BMS-935177
CAS:BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formula:C31H26N4O3Purezza:99.89%Colore e forma:SolidPeso molecolare:502.56TQ-3959
CAS:TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Formula:C40H47N11O5Colore e forma:SolidPeso molecolare:761.87(Rac)-Ibrutinib alkyne
CAS:(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Formula:C25H22N6O2Colore e forma:SolidPeso molecolare:438.48JAK3/BTK-IN-3
CAS:JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.Formula:C22H28N8OColore e forma:SolidPeso molecolare:420.51BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formula:C28H24FN5O2Colore e forma:SolidPeso molecolare:481.52BTK-IN-34
CAS:BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Formula:C22H29N3O4SPeso molecolare:431.55BTK inhibitor 18
BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.Formula:C29H25N5O4S2Colore e forma:SolidPeso molecolare:571.67BTK-IN-10
CAS:BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Formula:C25H24F2N4O2Colore e forma:SolidPeso molecolare:450.48BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formula:C31H24Cl2N4O4Colore e forma:SolidPeso molecolare:587.45HDHD4-IN-1
CAS:HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Formula:C12H22NO11PColore e forma:SolidPeso molecolare:387.28JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Formula:C21H25ClN8OColore e forma:SolidPeso molecolare:440.93BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Formula:C23H22FN5O3Colore e forma:SolidPeso molecolare:435.45BTK-IN-16
CAS:BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.Formula:C15H14N4O2Purezza:99.04%Colore e forma:SoildPeso molecolare:282.3JAK3/BTK-IN-7
CAS:JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].Formula:C29H30N8O4Colore e forma:SolidPeso molecolare:554.6BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Formula:C26H36N6O3Colore e forma:SolidPeso molecolare:480.6BTK-IN-32
CAS:BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Formula:C35H35ClN4O3SPeso molecolare:627.2G-744
CAS:G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).Formula:C29H29N5O3SPurezza:98%Colore e forma:SolidPeso molecolare:527.64GNE-431
CAS:GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Formula:C30H32N10O2Colore e forma:SolidPeso molecolare:564.64WS-11
CAS:WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Formula:C26H22FN9O2Colore e forma:SolidPeso molecolare:511.51
